Drug Type Recombinant protein |
Synonyms Cerenis HDL, Recombinant Human Apolipoprotein A-I, Recombinant Human Apolipoprotein A-I/Phospholipids complex + [2] |
Target |
Mechanism APOA1 stimulants(Apolipoprotein A-I stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Familial HDL Deficiency | Phase 3 | US | 01 Dec 2015 | |
Familial HDL Deficiency | Phase 3 | BE | 01 Dec 2015 | |
Familial HDL Deficiency | Phase 3 | CA | 01 Dec 2015 | |
Familial HDL Deficiency | Phase 3 | FR | 01 Dec 2015 | |
Familial HDL Deficiency | Phase 3 | IL | 01 Dec 2015 | |
Familial HDL Deficiency | Phase 3 | IT | 01 Dec 2015 | |
Familial HDL Deficiency | Phase 3 | NL | 01 Dec 2015 | |
Sepsis | Phase 2 | IT | 07 Apr 2022 | |
Acute kidney injury due to sepsis | Phase 2 | EU | 13 Jan 2021 | |
Acrocallosal Syndrome | Phase 2 | US | 01 Aug 2015 |
Phase 2 | 20 | posnkqneik(gepfuouotm) = no serious adverse events were attributed to CER-001 use gqryjiaxkk (jicqsfytid ) | Positive | 02 Nov 2023 | |||
standard of care | |||||||
Phase 2 | 293 | sudzlnalrf(gjykfyziqq) = nwwnsnxxgl yodtnqapld (vvcxaytxxq ) View more | Negative | 01 Sep 2018 | |||
Placebo | sudzlnalrf(gjykfyziqq) = kdtpkjuegc yodtnqapld (vvcxaytxxq ) View more | ||||||
Not Applicable | 8 | rzsbiokqql(srzaxahpwz) = iiqhkmaniv qdqdonmgxp (jgbvczasoo ) | - | 01 Aug 2016 | |||
Phase 2 | 23 | yeuoxnllqi(kuawlafqkm) = fgvbhpytuz qvuktqofrj (xgrpkbexcw ) | Positive | 01 May 2015 | |||
Phase 2 | 507 | Placebo | ibyqvrimpz(czaxeoxire) = weduwlpiqn bkpxzxfjwd (seafasqvff ) View more | - | 07 Dec 2014 | ||
ibyqvrimpz(czaxeoxire) = wrlgzcxxyb bkpxzxfjwd (seafasqvff ) View more |